Boehringer Ingelheim has discontinued development of its hypoactive sexual desire disorder drug Girosa after the FDA refused to approve it. …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

